Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374719 | 0.88 | TTR (0.53) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL1374718 | 0.88 | TTR (0.53) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL1410531 | 0.87 | TTR (0.51) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL30394050 | 0.87 | TTR (0.55) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL1373914 | 0.87 | TTR (0.55) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL1373913 | 0.87 | TTR (0.55) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL1410529 | 0.85 | TTR (0.50) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL1410534 | 0.85 | TTR (0.50) | TTRAPPPTPN1EPHX2CA12 | |
| SCHEMBL6477850 | 0.84 | TTR (0.56) | TTRCA12CA1CA2CA7 | |
| SCHEMBL69618 | 0.84 | TTR (0.66) | TTRAPPPTPN1EPHX2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | TTR 8/4885APP 1377/4885PTPN1 530/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | TTR 122/4885APP 2022/4885PTPN1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.